二肽基肽酶-4(dipeptidy1 peptidase-4,DPP-4)抑制药是近年研发的口服降糖药物,因其作用机制独特、疗效确定、低血糖发生率少、对体重中性作用或轻度降低、心血管安全性良好等特点而受到关注,临床应用也越来越广泛。DPP-4抑制药减少体内胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)的降解,从而增加循环GLP-1浓度2~3倍,GLP-1抑制α细 Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral hypoglycemic drugs developed in recent years because of their unique mechanism of action, curative effect, low incidence of hypoglycemia, moderate to moderate body weight or light Degree of reduction, good cardiovascular safety and other characteristics of attention, clinical application is also more and more widely. DPP-4 inhibitors reduce the degradation of glucagon-like peptide-1 (GLP-1) in vivo, thereby increasing the concentration of circulating GLP-1 by 2 to 3 folds. GLP-1 inhibits α-fine